IGM Biosciences, Inc.

Good day, everyone, and welcome to the IGM Biosciences Fourth Quarter and Full Year 2020 Financial Results Call. Today's call is being recorded. At this time, I'd like to turn the call over to Ms. Bethahir, Chief Financial Officer of IGM.

Thank you, Operator. Welcome and thank you to those of you joining us today to discuss IGM's Fourth Quarter and Full Year 2020 Financial Results. With me this afternoon to discuss the financial results and to provide a general corporate update are Fred Schwarzer, Chief Executive Officer, Bruce Kite, Chief Scientific Officer, Dan Chen, Chief Medical Officer, and Lisa Decker, Chief Business Officer. Please note that we will be making forward-looking statements on this call, including statements about IGM's plans, expectations and forecasts, and about future events. Actual results may differ materially as a result of various risks and uncertainties including those discussed in the company's most recent annual report on Form 10-K, as well as its other filings with the SEC. Any forward-looking statements represent IGM's views as of today, March 30, 2021 only, and the company disclaims any obligation to update these statements except as required by law. Following this call, a replay will be available on the company's website, www.igmbio.com, With that, I will now turn the call over to Fred.

Thank you, Mispo. Good afternoon, everyone. Thank you for joining us on this call to discuss our fourth quarter and full year 2020 financial results. Before we begin, it is my great pleasure to introduce Lisa Decker as our new Chief Business Officer. Lisa brings a wealth of life sciences business development experience to IGM, and I'm very pleased to welcome her to our executive team. 2020 was an important year for IGM. Among our milestones last year, we presented the first clinical data from our Phase I trial of IGM2323, our bispecific IGM antibody targeting CD20 and CD3. and these were presented at the ASH 2020 Annual Meeting. We were highly encouraged by these initial data from both an efficacy and a safety perspective. We continue to make good progress through our IGM 2323 dose escalation cohorts, and we are pleased with the safety and efficacy profile that we have seen so far. We look forward to completing enrollment in the phase one dose escalation and initial expansion cohorts and establishing a recommended phase two dose later this year and provide an operational update on this ongoing trial. During 2020, we also began clinical development of IgM 8444, our IgM DR5 agonist antibody, which we believe may have application in the treatment of a broad range of cancer types. As Dan will shortly describe, we have now cleared the second dose cohort in our monotherapy dose escalation protocol, and we are ready to expand into higher dose cohorts and combination therapy. Bruce will describe some of the exciting preclinical data we've generated concerning IgM 8444 in combination with brinopant, a clinical stage apoptosis drug which is synergistic with IgM 8444 and to which we obtained exclusive global rights earlier this year. Finally, as Bruce will also describe, we are very excited about the prospects for IgM 7354, our targeted IL-15 immune cell stimulating antibody, as well as our broader pipeline. We plan to file an IND for IgM 7354 towards the end of this year and to file an IND for our CD38 by CD3 T-cell engager candidate next year. With that, I'll turn the call over to Dan who will discuss IgM 2323 and IgM 8444 and the current state of our clinical trials.